Insider trade

Officer received an award of 2,220 HAE shares

Traded May 15, 2026 · Filed May 19, 2026

HaemoneticsHAE

2,220
Shares

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 15, 2026
Reporting period: Not applicable
Filed with the SEC: May 19, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000313143-26-000045
Filed / recorded

May 19, 2026, 9:33 PM UTC

Added to OQRO

Oct 6, 2026, 7:59 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

HAEMONETICS CORP

Issuer CIK

313143

Ticker

HAE

Reporting person

Farris Maryanne Maunsell

Relationship

Officer

Officer title

VP, Chief Accounting Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

May 15, 2026

Transaction code

A

Shares / units

2,220

Acquired / disposed

Acquired (A)

Shares owned after

6,501

Ownership form

Direct

Amendment

No

Footnotes from the filing

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
This number includes unvested RSUs previously reported.